Phreesia, Inc.
NYSEPHR Raymond James downgrades to Market Perform from Outperform, trimming conviction on healthcare software amid persistent growth headwinds. Stock at $10.94, down 10% over past week.
Why this matters: Raymond James just pulled its Outperform rating on PHR. The downgrade landed on a stock already down 10% in a week. Yet options traders moved in the opposite direction — aggressively. The Q2 print on…
PHR is heading into a second earnings event on September 4 with the Q2 print already absorbed and investors now focused on whether management's forward guidance can close the gap between the stock and analyst…
Snapshot as of 16 Sept 2026
PHR reported Q2 results on September 2 and the market is now pricing the aftermath, with the stock closing at $11.84 — down 3% on the day but up 2.8% for the week, a pattern that suggests Tuesday's initial reaction…
PHR enters its September 2 earnings release with an activist shareholder dominating the register and a stock that has clawed back ground but remains deeply underwater for the year. The dominant ownership story is Pale…
Phreesia reports today with the stock at $9.13 — a level that two of the most recently active analysts now consider fair value, and well below where the rest of the Street still sits. The analyst picture heading into…
Phreesia heads into its May 27 earnings call carrying fresh analyst downgrades, an active securities class action, and a stock trading near $9 — a long way from where the Street was targeting it just two months…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PHR — free to start on ORTEX.
Sign up for free →Open PHR on ORTEX